Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection.
Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection.
复制标题
VSIG4低表达与乙型肝炎感染肝细胞癌患者预后不良相关
DOI：
10.2147/cmar.s165822
复制
发表时间：
2018
影响因子：
3.3
通讯作者：
Chen Y
中科院分区：
文献类型：
--
作者：
Zhu S;Tan W;Li W;Zhou R;Wu X;Chen X;Li W;Shang C;Chen Y
V-SET和免疫球蛋白结构域包含蛋白4(VSIG4)在肿瘤发生中起重要作用。然而，其在肝细胞癌中的表达和临床相关性仍不清楚。首先，从癌症基因组图谱(TCGA)和基因表达总览数据库中筛选出肝细胞癌的mRNA图谱。VSIG4是一个在肝细胞癌中未见报道的差异表达基因。其次，分析TCGA中VSIG4的表达与肝癌患者预后的关系。第三，应用聚合酶链式反应技术检测了36对肝癌组织和4株肝癌细胞系中VSIG4的表达水平。并对36例不同VSIG4表达水平的肝细胞癌患者进行预后分析。生物信息学分析显示，VSIG4在肝细胞癌组织中表达下调，其表达水平与血清甲胎蛋白(AFP)水平和肿瘤远处转移呈负相关。TCGA中所有肝癌患者的生存分析表明，总生存期和无瘤生存期与VSIG4的表达无明显相关性。然而，亚组分析显示，在乙肝病毒相关性肝癌患者中，VSIG4低表达组的总生存期和无瘤生存期都较短。我们的聚合酶链式反应结果进一步显示VSIG4在肝癌组织和肝癌细胞系中的表达显著降低，并且VSIG4低表达的乙肝相关性肝癌患者的无病生存期短于VSIG4高表达的患者，这与生物信息学分析结果一致。我们的研究提示VSIG4在肝细胞癌中表达下调，在乙肝病毒相关性肝细胞癌患者中，VSIG4的低表达与预后不良有关。
V-set and immunoglobulin domain containing protein 4 (VSIG4) was reported to play an important role in tumorigenesis. However, the expression and clinical relevance in hepatocellular carcinoma (HCC) remain unknown. First, the mRNA profiles of HCC were screened from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases. VSIG4, a differentially expressed gene that has not been reported in HCC, was distinguished. Second, the correlation between VSIG4 expression and the prognosis of HCC patients from TCGA was analyzed. Third, VSIG4 mRNA level was detected in 36 pairs of HCC tissues and 4 HCC cell lines by PCR assay. And finally, prognosis analysis was assessed for 36 HCC patients with different expression levels of VSIG4. Bioinformatics analysis showed that VSIG4 expression was downregulated in HCC tissues, and the expression level of VSIG4 was negatively correlated with serum alpha fetal protein (AFP) level and tumor distant metastasis. Survival analysis of all HCC patients in TCGA indicated that the overall survival and disease-free survival were not significantly associated with VSIG4 expression. However, subgroup analysis showed that in the patients with hepatitis B virus-related HCC, both overall survival and disease-free survival were shorter in the low VSIG4 expression group. Our PCR results further showed that VSIG4 expression was significantly decreased in HCC tissues and HCC cell lines, and the disease-free survival in hepatitis B virus-related HCC patients with low VSIG4 expression was shorter than in those with high VSIG4 expression, which was consistent with the bioinformatics analysis results. Our study suggests that VSIG4 is downregulated in HCC, and low expression of VSIG4 is associated with poor prognosis in hepatitis B virus-related HCC patients.